Atossa Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Atossa Therapeutics (ATOS).

Price Target Range — 12 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$21Upside to Avg. PT+795.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$24→$25
Jul 7, 2026	Rodman & Renshaw	Michael G. King Jr.	Initiate	Buy	$12
Apr 10, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$120→$24
Mar 26, 2026	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$7→$25
Dec 8, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Sep 22, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$8
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$8
Jun 5, 2025	Craig-Hallum	Albert Lowe	Initiate	Buy	$4
Apr 21, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$7
Mar 26, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Mar 12, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Jan 30, 2025	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Dec 13, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$7
Dec 12, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	—
Dec 9, 2024	Ascendiant Capital	Edward Woo	PT Raise	Buy	$7→$7
Nov 13, 2024	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$6→$7
Nov 5, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6
Oct 31, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6
Sep 11, 2024	Ascendiant Capital	Edward Woo	PT Raise	Buy	$6→$7
Aug 12, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$6

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $24 to $25.

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Atossa Therapeutics (NASDAQ:ATOS) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and lowers the price target from $120 to $24.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

HC Wainwright & Co. analyst Emily Bodnar maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7 to $25.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.75 to $8.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $7.5 to $7.75.

Benzinga Newsdesk

Atossa Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Atossa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

People Also Watch

People Also Watch

Atossa Therapeutics Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Atossa Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRORodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PROHC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PROAscendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Rodman & Renshaw Initiates Coverage On Atossa Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Lowers Price Target to $24

PRO
HC Wainwright & Co. Maintains Buy on Atossa Therapeutics, Raises Price Target to $25

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $8

PRO
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $7.75